Dare Bioscience regains compliance with Nasdaq minimum bid price rule

Dare Bioscience announced that it was notified by the Nasdaq Office of General Counsel that the Company regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company’s common stock being $1.00 per share or greater for 10 consecutive trading sessions and that the matter is closed. “We are thrilled to announce that we have regained compliance with the Nasdaq minimum bid price rule,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. “This strengthens our position in the market and enhances our ability to drive our vision forward. We look forward to the opportunity to accelerate our development efforts on key programs in our portfolio and to ultimately provide great therapeutic options for women.”